KR101165718B1 - A composition comprising the Angelica dahurica Bentham et Hooker extract there of having anti-asthmatic effect - Google Patents

Abstract

The present invention relates to a composition containing a blanched extract having anti-asthmatic activity, and more particularly, to a composition for preventing or treating asthma containing an extract of Angelica dahurica Bentham et Hooker extracted with water, alcohol or a mixture thereof ≪ / RTI > The composition containing the blanched extract of the present invention can be usefully used as a pharmaceutical composition for the prevention and treatment of asthma, or as a health supplement food or a health functional food.

Blankets (Angelica dahurica Bentham et Hooker), asthma, mucus secretion.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition containing an extract of Bleach with anti-asthmatic activity,

The present invention relates to a pharmaceutical composition having anti-asthmatic activity.

Asthma is a disorder characterized by airway hyperresponsiveness to various stimuli. Clinical manifestations such as wheezing, dyspnea, and cough caused by extensive stenosis of the airways can be reversed by natural healing or by treatment. Can be improved. Asthma can be divided into extrinsic asthma and endogenous asthma depending on its cause. In the case of exogenous asthma, it refers to asthma that causes symptoms when exposed to a causative antigen. The skin test or bronchial challenge test for the causative antigen is positive, and the onset age is usually young. In Korea, house dust mite is the most common cause antigen, and pollen, animal epithelium, mold, etc.

Steroid agents such as glucocorticoid have been used for asthma treatment so far known. However, the steroid agent is strong in terms of effect, but has a problem of serious adverse side effects. Accordingly, the development of a therapeutic agent having excellent effects and less side effects is urgently required, and a therapeutic agent using natural substances extracted from plants is being developed.

Bentham et Hooker ( Angelica dahurica Bentham et Hooker) has a long spindle with a length of 10 ~ 25 ㎝ and a grayish brown or dark brown color. There is a little leaf sheath on the top of the roots, and there is a narrowly marked rounded node. The roots have vertical wrinkles and several fine roots that are noticeable in the vertical direction. Around the cut side, there are many gaps with grayish white color, and the middle part is dark brown. From ancient times, white paper is an analgesic drug that regulates headache, nasal congestion, and nasal discharge caused by influenza, and is effective for gastrointestinal disorders, postpartum headache, dizziness, toothache, facial nerve pain, paralysis. In addition, when menstrual bleeding, fever, and feces are mixed with blood, headache due to empyema, rejuvenation, poisoning, and skin ulcers are also effective.

It is known that the pharmacological action to date is antimicrobial action, animal vascular exercise center, respiratory center, vagus nerve and spinal cord excitatory action, coronary artery blood flow increasing action, white wind wind, Disease: Chronic dermatosis has been reported to be effective in the development of multiple scales of white scale on the skin surface due to erythema and palsy. However, there is no report that white paper has anti-asthmatic effects.

Accordingly, the present inventors have made intensive efforts to search for plant materials that can be used for the treatment of asthma. As a result, the present inventors have found that the extract of Angelica dahurica Bentham et Hooker extracts bronchial mucus secretion in pulmonary bronchial tissues in an asthmatic animal model sensitized with ovalbumin The present invention has been accomplished by confirming the efficacy of a white solid for treating asthma by having an inflammatory cell infiltration inhibitory activity.

It is an object of the present invention to provide a composition for preventing or treating asthma containing an extract of Angelica dahurica Bentham et Hooker as an active ingredient, and a method of preventing or treating asthma using the composition.

It is still another object of the present invention to provide a health food for preventing or ameliorating asthma containing an extract of Bleach as an active ingredient.

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating asthma, which contains, as an active ingredient, an extract of Angelica dahurica Bentham et Hooker extracted with water, alcohol or a mixture thereof.

The present invention also provides a health food for preventing or ameliorating asthma containing, as an active ingredient, a white-leaf extract extracted with water, an alcohol or a mixture thereof.

In addition, the present invention provides a method of preventing or treating asthma in a subject comprising administering to the subject a pharmaceutically effective amount of the above-mentioned blank white extract.

The extract of Angelica dahurica Bentham et Hooker of the present invention has bronchial mucus secretion and inflammatory cell infiltration inhibitory activity in pulmonary bronchial tissues in an ovalbumin-sensitized asthma animal model, so that the active ingredient of the composition for improving or treating asthma . ≪ / RTI >

Hereinafter, terms used in the present invention will be described.

The term "prophylactic " as used herein refers to any act that inhibits asthma by administration of the composition of the present invention.

As used herein, the terms " treatment "and" improvement "refer to all actions by which administration of the composition of the present invention improves or alleviates asthma.

The term "administering" as used herein is meant to provide any desired composition of the invention to an individual by any suitable method.

The term "individual" as used herein refers to all animals, including humans, monkeys, dogs, goats, pigs or rats, who have been asthmaticized by administering the composition of the present invention.

The term " pharmaceutically effective amount " as used herein means an amount sufficient to treat a disease at a reasonable benefit or risk rate applicable to medical treatment, including the type of disease, severity, activity of the drug, The time of administration, the route and rate of excretion of the drug, the duration of the treatment, factors including drugs used simultaneously and other factors well known in the medical arts.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for prevention or treatment of asthma containing an extract of Angelica dahurica Bentham et Hooker as an active ingredient.

The blanched extract may be prepared by the following steps, but is not limited thereto:

1) extracting dry white paper ( Angelica dahurica Bentham et Hooker) by adding an extraction solvent;

2) filtering the extract of step 1); And

3) Concentrating the filtered extract of step 2) under reduced pressure.

In the above method, the white paper of step 1) may be used without limitation such as cultivated or commercially available.

The extraction solvent is preferably a solvent selected from water, an alcohol or a mixture thereof, preferably a C ₁ to C ₄ lower alcohol or a mixed solvent thereof, more preferably an aqueous 70% ethanol solution, But is not limited thereto. The amount of the extraction solvent is 2 to 15 times the dry weight of the white paper. The extraction method may be an extraction method such as hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction. Preferably, the extraction method may be performed once to five times by an ultrasonic extraction method. The extraction temperature is preferably in the range of 10 ° C to 100 ° C, more preferably room temperature. The extraction time is 30 minutes to 4 hours, preferably 1 to 2 hours.

In the above method, it is preferable, but not limited, to use a vacuum rotary evaporator for the vacuum concentration in step 3). The drying is preferably performed by lyophilization, but is not limited thereto.

In a specific embodiment of the present invention, the extract of Angelica dahurica Bentham et Hooker is used in the ovalbumin-sensitized asthma model in the immunoglobulin E (IgE) and interleukin-4 (IL-4) 5 (IL-5) production, eosinophilia-suppressing activity, inhibition of bronchial inflammatory cell infiltration and recovery of epithelial cell damage in pulmonary bronchial tissues (see FIGS. 1 to 5 ). In addition, the bronchial remodeling process in asthmatic patients causes a decrease in lung function over time, and the white bark extract of the present invention suppresses the secretion of mucus that can be generated by the reforming process (see FIG. 6) . The mechanism of the asthmatic response is through a variety of responses involving a variety of cells, regulators, and mediators involved in characteristic inflammatory responses and tissue remodeling. ALT and AST levels of hepatotoxicity were measured using a commercial kit to determine whether the white fly extract was toxic to the asthmatic animal model used in this experiment.

Therefore, it can be seen that the white bark extract of the present invention can be effectively used as a pharmaceutical composition for preventing or treating asthma that is involved in inflammation reaction and tissue remodeling.

The pharmaceutical composition containing the blanched extract of the present invention preferably contains the blanched extract in an amount of 0.1 to 50% by weight based on the total weight of the composition, but is not limited thereto.

The pharmaceutical composition comprising the white ginseng extract of the present invention may further comprise suitable carriers, excipients and diluents conventionally used in the production of pharmaceutical compositions.

The pharmaceutical composition containing the blanched extract according to the present invention may be formulated into oral compositions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppositories and sterilized injection solutions Can be used. Examples of carriers, excipients and diluents that can be included in the composition containing the extract include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. In the case of formulation, a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose ), Lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, simple diluents commonly used, various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin and the like.

The preferred dose of the blanched extract of the present invention varies depending on the condition and the weight of the patient, the degree of disease, the drug form, the administration route and the period, but can be appropriately selected by those skilled in the art. However, in order to obtain the desired effect, it is preferable that the blanched extract of the present invention is administered at 0.0001 to 1 g / kg per day, preferably 0.001 to 200 mg / kg per day. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally, and parenteral administration can be performed by external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, But is not limited thereto.

The present invention also provides a health food for preventing or ameliorating asthma containing an extract of Bleach as an active ingredient.

In the present invention, it was confirmed that the BAC extract inhibited the inflammatory reaction of the bronchoalveolar lavage fluid and bronchial mucus secretion inhibitory activity in the asthmatic animal model (see FIGS. 1 to 6) and found that there was no toxicity, The present invention can be effectively used as a health food for preventing or ameliorating osteoporosis.

There is no particular limitation on the kind of the food. Examples of the foods to which the above substances can be added include dairy products including dairy products such as drinks, meat, sausage, bread, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, Beverages, alcoholic beverages, and vitamin complexes, all of which include health foods in a conventional sense.

The white paper extract of the present invention can be added directly to the food or can be used together with other food or food ingredients, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be suitably determined according to its use purpose (for prevention or improvement). Generally, the amount of the extract in the health food may be 0.01 to 15% by weight of the total food, and the health beverage composition may be added in a proportion of 0.02 to 5 g, preferably 0.3 to 1 g, based on 100 ml have. However, in the case of long-term ingestion intended for health and hygiene purposes or health control purposes, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount in the above range.

The health functional beverage composition of the present invention has no particular limitation on the other ingredients other than the above-mentioned extract as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 ml of the composition of the present invention.

In addition to the above, the white ginseng extract of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and aging agents (cheese, chocolate etc.), pectic acid and its salts, Salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. In addition, the blank white extract of the present invention may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The ratio of such additives is not so important, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the white paper extract of the present invention.

The present invention also provides a method of treating asthma comprising administering to a subject suffering from asthma with a pharmaceutically effective amount of a blank white extract or a composition comprising the same.

The present invention also provides a method of preventing asthma comprising administering to a subject a pharmaceutically effective amount of a white-ground extract or a composition comprising the same.

The subject is a vertebrate animal, preferably a mammal, more preferably an experimental animal such as a mouse, a rabbit, a guinea pig, a hamster, a dog or a cat, and most preferably an ape-like animal such as a chimpanzee or a gorilla.

The above-mentioned administration method may be oral or parenteral administration. In the case of parenteral administration, intraperitoneal injection, intramuscular injection, subcutaneous injection, intravenous injection, intramuscular injection, intramural injection, intracerebroventricular injection, Can be administered by injection.

The pharmaceutically effective amount is 0.0001 to 1 g / kg, preferably 0.001 to 200 mg / kg, but is not limited thereto. The dose may vary depending on the weight, age, sex, health condition, diet, administration period, administration method, elimination rate, severity of disease, etc. of asthmatic patients.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples and Preparation Examples illustrate the present invention specifically, and the contents of the present invention are not limited by Examples, Experimental Examples and Preparation Examples.

≪ Example 1 > Preparation of white paper extract

( Angelica dahurica Bentham et Hooker) was purchased from HMAX (Jecheon, Korea) and crushed after emotionally received from Dongguk University professor Lee Hyun. The dried white paper was pulverized using a pulverizer, and 200 g of the extract was ultrasonically extracted with 70% EtOH (2 L × 3 times) at room temperature for 1 hour. The total extract was concentrated under reduced pressure to obtain 62.19 g of 70% EtOH extract (yield 31.1%) .

EXPERIMENTAL EXAMPLE 1 Eosinophil Analysis of Bronchoalveolar Lavage Fluid

<1-1> Airway sensitization and antigen administration of experimental animals

(BALB / c) (approximately 20 g) was purchased from Korea BioLink Co., Ltd., and 2 mg aluminum hydroxide (Sigma A8222) and 20 μg of egg white albumin (Sigma A5503) (PH 7.4) suspended in phosphate-buffered saline was sensitized by intraperitoneal injection twice at intervals of two weeks. On the 21st day, 22nd day, and 23rd day after the start of the experiment, a phosphate buffer solution containing 1% albumin albumin was sprayed into a container containing a mouse for 30 minutes using an ultrasonic atomizer, and a negative control group (C: 8 animals) as a positive control group, and the control group was treated with 50 mg / kg of PBS after airway sensitization (group B: 8 animals) 1 &gt; were suspended in phosphate buffered saline and then treated with 25, 50 or 100 mg / kg orally administered group (D and E: 8) one hour prior to antigen administration. Twenty-four hours after the last antigen challenge, an excessive amount of pentobarbital (Sigma P3761) was administered, and the blood was collected and bronchial incision was performed. Bronchoalveolar lavage fluid (BALF) was obtained by inhalation of 0.6 ml three times by cannula insertion method in the organ.

<1-2> Eosinophil analysis of bronchoalveolar lavage fluid in animal models sensitized with albumin albumin

100 ㎕ of bronchial alveolar fluid obtained from each experimental group obtained in Experimental Example <1-1> was placed on a slide and centrifuged using a cytospin instrument (Hanil, Korea) to fix the cells on the slide. The total number of cells, excluding dead cells, stained with trypan blue was calculated using a hemocytometer and repeated three times (Daigle I & Simon HU, Swiss Med. Wkly., 131: 231-237 , 2001). The number of eosinophils was determined by staining with a Diff-Quick reagent (Sysmex, Cat No. 38721, Switzerland) and counted in the same manner as the total number of cells. Statistical analysis was performed with the ANOVA test (Duncan) and was significant at P <0.05.

As a result, as shown in Table 1 and FIG. 1, the total number of inflammatory cells of the bronchial alveolar fluid without airway sensitization was 248 ± 79 × 10 ⁴ cells / ㎖ as a negative control group, of which eosinophil ) Was 0%. As a positive control, sensitization with ovalbumin and administration of PBS followed by administration of PBS resulted in a total inflammatory cell count of 7858 ± 1171 × 10 ⁴ cells / mouse and a 30-fold increase in eosinophil count Respectively. However, in the case of treatment of the blanched extract of the present invention, 50, and 100 mg / kg, respectively, compared to the montelukast positive control (Table 1 and Fig. 1).

Kinds Per mouse
Total number of inflammatory cells (million) Per mouse
Eosinophil count (million) Normal mouse 248 ^a + 79 0 ^a 0 I albumin sensitization-treated with phosphate buffer solution 7858 ^b ± 1171 3506 ^b ± 682 AD-25; albumin sensitization-white paper (25 mg / kg) extract treatment 4200 ^e + - 764 2231 ^d + 498 AD-50; albumin sensitization-white paper (50 mg / kg) extract treatment 2880 ^{c, d} ± 629 1313 ^c ± 400 AD-100; albumin sensitization-white paper (100 mg / kg) extract treatment 2488 ^c ± 1077 1222 ^c 533 I Am Albumin Sensitization - Monterocaster Treatment 3604 ^{d, e} + 785 1682 ^c ± 459

<Experimental Example 2> Immunoglobulin E (IgE) analysis

Immunoglobulin E (IgE) The sandwich-type enzyme-linked immunosorbent assay (ELISA) was used for the analysis.

Specifically, 100 μl of the bronchial alveolar fluid of each experimental group obtained in the above Experimental Example <1-1> was put into a 96-well plate with capturing IgE antibody and incubated for 1 hour at room temperature with antigen- The plate with immunoglobulin E was blocked with 5% non-fat milk powder for 1 hour and then washed three times with PBS (0.1% Tween 20). After the antigen-antibody reaction was completed, the cells were washed three more times, and then 100 μl of a detection IgE antibody (mouse, PharMingen, San Diego, USA) to which horseradish peroxidase (HRP) And allowed to react for 1 hour. After the reaction, the cells were washed 5 times with a washing solution, and the color development reaction was induced by using o-phenylene diamine (OPD) and hydrogen peroxide (H ₂ O ₂ ) as substrates, and the absorbance was measured at 405 nm. The content of immunoglobulin E in bronchoalveolar lavage fluid was measured. Statistical analysis was performed with the ANOVA test (Duncan) and was significant at P <0.05.

As a result, as shown in Table 2 and FIG. 2, it was confirmed that the immunoglobulin E content in rats sensitized with ovalbumin was significantly increased in the rats treated with phosphate buffer alone, Compared with buffer solution, immunoglobulin E production was significantly decreased by 32% when 100 mg / kg and 50% by 100 mg / kg, respectively (Table 2 and Table 3) 2).

Kinds Immunoglobulin E content (ng / mL) Immunoglobulin E formation inhibition rate (%) Normal rat 0.86 ^a ± 0.39 I albumin sensitization-treated with phosphate buffer solution 17.91 ^b ± 2.80 0 AD-25; albumin sensitization-white paper (25 mg / kg) extract treatment 16.32 ^b ± 1.89 5 AD-50; albumin sensitization-white paper (50 mg / kg) extract treatment 12.11 ^c 1.23 32 AD-100; albumin sensitization-white paper (100 mg / kg) extract treatment 10.67 ^c ± 2.21 40 I Am Albumin Sensitization - Monterocaster Treatment 10.52 ^{c &lt; / RTI} &gt; 40

Experimental Example 3: Analysis of cytokine (IL-4, IL-5)

In order to measure the contents of cytokines IL-4 and IL-5 in the bronchial alveolar lavage fluid obtained in each of the experimental groups obtained in Experimental Example 1-1, (Biosource, USA) was used to measure the content of each cytokine according to the manufacturer's method. Statistical analysis was performed with the ANOVA test (Duncan) and was significant at P <0.05.

As a result, as shown in Table 3, FIG. 3 and FIG. 4, in the case of rats sensitized with ovalbumin, the production of interleukin-4 and interleukin-5 in the bronchial alveolar fluid was significantly increased, The inhibitory effect of interleukin - 4 and interleukin - 5 on IL - 4 and IL - 5 at 50 mg / kg and 100 mg / kg, respectively, (Table 3, Fig. 3 and Fig. 4).

Kinds IL-4 (pg / mL) IL-5 (pg / mL) Normal rat 37.80 ^a + 26.21 83.69 ^a ± 29.61 I albumin sensitization-treated with phosphate buffer solution 91.95 ^b ± 22.18 153.67 ^b ± 46.57 AD-25; I albumin sensitization - blank (25 mg / kg) extract treatment 74.41 ^{b, c} ± 16.27 131.78 ^{b, c} ± 29.69 AD-50; I albumin sensitization - white paper (50 mg / kg) extract treatment 56.82 .alpha. ^,. + -. 13.60 104.17? ^, ? + 18.67 AD-100; I albumin sensitization - white paper (100 mg / kg) extract treatment 41.75 ^a ± 20.83 86.76 ^a ± 19.43 I Am Albumin Sensitization - Monterocaster Treatment 70.59 ^{b, c} ± 22.11 86.76 ^a ± 19.43

<Experimental Example 4> Identification of anti-asthmatic effect using histopathological method

For histopathological experiments, rat lung tissue was fixed with 10% neutral buffer-formalin for 24 hours and then subjected to paraffin embedding. The embryonic tissue was cut into 4 μm thick sections and stained with hematoxylin and Eosin Y (ThermoShandon, USA), followed by Dako-inclusion (Dakocytomation, Denmark). After the dyeing and filling, the slide was examined with an optical microscope.

As a result, as shown in FIG. 5, in the control group (B) in which asthma was induced by the albumin albumin and only the phosphate buffer solution was administered, many inflammatory cells including eosinophils were invaded around the bronchioles and the epithelial cells were damaged On the other hand, inflammatory cells including eosinophils were markedly decreased in the experimental group treated with the blank extract (D and E) (Fig. 5).

<Experimental Example 5> Effect of inhibiting bronchial mucus

When bronchial remodeling occurs, excessive sticky mucus secretion occurs. In order to examine whether goblet cells, which secrete mucus, are excessively proliferating, the lung tissue sections of Experimental Example 4 were treated with periodic acid -Schiff (PAS, IMEB INC).

6, hyperplasia of goblet cells was observed in bronchial albumin-induced rat bronchus (B), whereas hyperplasia was not observed in the experimental group treated with white-fly extract (D and E) (Fig. 6 ).

<Experimental Example 6> Changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST)

After the end of the experiment, the separated blood was centrifuged at 3000 rpm for 10 minutes, and the supernatant was taken. The levels of AST and ALT were checked using a kit (BECKMAN coulter, Inc., Fullerton, CA, USA).

As a result, as shown in FIG. 7, ALT and AST were elevated in the montelukast group, which was a positive control group, compared with the control group. However, in the experimental group administered with the white fly extract, asthma was induced by ovalbumin albumin, There was little change in ALT and AST levels compared to the control group (Fig. 7).

Hereinafter, a preparation example of a pharmaceutical composition containing the white bark extract of the present invention will be described, but the present invention is not intended to be limited thereto but is specifically explained.

&Lt; Formulation Example 1 > Preparation of powders

Blank extract 500 mg

Lactose 100 mg

10 mg of talc

The above components are mixed and filled in airtight bags to prepare powders.

&Lt; Formulation Example 2 > Preparation of tablet

Blank extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.

&Lt; Formulation Example 3 > Preparation of capsule agent

Blank extract 500 mg

Corn starch 100 mg

Lactose 100 mg

2 mg of magnesium stearate

The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.

&Lt; Formulation Example 4 > Preparation of injection

Blank extract 500 mg

Sterile sterilized water for injection

pH adjuster

(2 ml) per ampoule in accordance with the usual injection method.

&Lt; Formulation Example 5 > Preparation of liquid agent

100 mg of blank white extract

10 g per isomer

5 g mannitol

Purified water quantity

Each component was added to purified water in accordance with the usual liquid preparation method and dissolved, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was adjusted to 100 ml with purified water, And sterilized to prepare a liquid preparation.

&Lt; Formulation Example 6 > Preparation of health food

Blank extract 1000 mg

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B ₂

0.5 mg of vitamin B ₆

Vitamin B ₁₂ 0.2 g

10 mg vitamin C

Biotin 10 μg

Nicotinic acid amide 1.7 mg

50 ㎍ of folic acid

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

15 mg of potassium phosphate monobasic

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

100 mg of calcium carbonate

24.8 mg of magnesium chloride

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

&Lt; Formulation Example 7 > Preparation of health drink

Blank extract 1000 mg

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added to a total of 900 ml

The above components were mixed according to a conventional health drink manufacturing method, and the mixture was stirred and heated at 85 ° C for about 1 hour. The resulting solution was filtered and sterilized in a 2-liter sterile container. The resulting solution was refrigerated, And used in the preparation of the composition.

Although the compositional ratio is relatively mixed with a component suitable for a favorite drink, it is also possible to arbitrarily modify the compounding ratio according to the regional or national preference such as the demand class, the demanding country, and the use purpose.

The white ginseng extract of the present invention can be used as a pharmaceutical composition for the prevention and treatment of asthma, or as a health supplement food or a health functional food.

FIG. 1 is a graph showing the effect of a blank ( Angelica dahurica Bentham et Hooker) extract on the total number of inflammatory cells and eosinophils in bronchoalveolar lavage fluid after airway sensitization.

2 is a graph showing the results of measurement of the content of immunoglobulin E in the alveolar lavage fluid.

3 is a graph showing the results of measurement of the content of interleukin 4 in the alveolar lavage fluid.

4 is a graph showing the results of measurement of the content of interleukin 5 in the alveolar lavage fluid.

Figure 5 shows the histochemical results of bronchoalveolar tissue after airway sensitization:

(A) If you are not sensitizing yourself to prayer;

(B) airway sensitization with albumin albumin;

(C) treated with montelukast;

(D) treated with 25 mg / kg of a blank extract;

(E) treated with 50 mg / kg of a blank white extract; And

(F) When treated with 100 mg / kg of blank white extract.

Figure 6 shows PAS staining of the bronchi after airway stimulation:

(A) If you are not sensitizing yourself to prayer,

(B) airway sensitization with albumin albumin;

(C) treated with montelukast;

(D) treated with 25 mg / kg of a blank extract;

(E) treated with 50 mg / kg of a blank white extract; And

(F) When treated with 100 mg / kg of blank white extract.

7 is a graph showing the results of measurement of levels of ALT and AST in serum.

Claims (8)

A pharmaceutical composition for preventing or treating asthma, which contains, as an active ingredient, an extract of Angelica dahurica Bentham et Hooker extracted with water, a C ₁ to C ₄ lower alcohol or a mixture thereof. delete The pharmaceutical composition for preventing or treating asthma according to claim 1, wherein the lower alcohol is ethanol or methanol. A health food for preventing or ameliorating asthma comprising, as an active ingredient, an extract of Angelica dahurica Bentham et Hooker extracted with water, ethanol or a mixture thereof. delete delete A method for treating asthma comprising administering a pharmaceutically effective amount of an extract of Angelica dahurica Bentham et Hooker to a mammal other than a human suffering from asthma. A method for preventing asthma comprising administering a pharmaceutically effective amount of an extract of Angelica dahurica Bentham et Hooker to mammals other than humans.

Images